Thorax

Proteomics-based risk prediction and drug targets identification for chronic obstructive pulmonary disease

Background Chronic obstructive pulmonary disease (COPD) is a leading cause of global mortality, yet existing risk prediction models remain limited. This study aimed to develop and validate a ...
thorax.bmj

Use of inhaled corticosteroids in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)

Introduction Current bronchiectasis guidelines advise against the use of inhaled corticosteroids (ICS) except in patients with associated asthma, allergic bronchopulmonary aspergillosis (ABPA) and/or ...
thorax.bmj

British Thoracic Society Clinical Statement on Pulmonary Arteriovenous Malformations

Correspondence to Professor Claire L Shovlin, Professor of Practice (Clinical and Molecular Medicine), NHLI Vascular Science, Imperial College London, Imperial Centre for Translational and ...
thorax.bmj

The rising incidence of idiopathic pulmonary fibrosis in the UK

Background Previous studies have shown that the incidence of idiopathic pulmonary fibrosis (IPF) is rising in the UK and USA. Death registrations and primary care data were used to determine the ...
thorax.bmj

Pulmonary rehabilitation and quality of life in alpha-1 antitrypsin deficiency: findings from a retrospective cohort study

Alpha-1 antitrypsin deficiency (AATD) is a rare genetic disorder associated with early-onset chronic obstructive pulmonary disease and impaired quality of life (QoL). This retrospective study ...
thorax.bmj

The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease

a Department of Respiratory Medicine, Glenfield Hospital, Leicester LE3 9QP, UK, b Department of Sports Science, Loughborough University of Technology, UK Dr S M Revill. BACKGROUND The purpose of this ...
thorax.bmj

Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme

BACKGROUND Pulmonary rehabilitation programmes improve the health of patients disabled by lung disease but their cost effectiveness is unproved. We undertook a cost/utility analysis in conjunction ...
thorax.bmj

Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma

4 Department of Pneumology, H Universitario La Fe, Valencia, Spain 5 Department of Pneumology, H de Cruces, Vizcaya, Spain 6 Department of Pneumology, H Carlos Haya, Málaga, Spain 7 Department of ...
thorax.bmj

Pulmonary eosinophilia associated with montelukast

Antileukotriene drugs are new therapeutic agents that have recently been approved for the treatment of asthma. Several cases of eosinophilic conditions including Churg-Strauss syndrome have been ...
thorax.bmj

β-Actin and GAPDH housekeeping gene expression in asthmatic airways is variable and not suitable for normalising mRNA levels

1 Department of Respiratory Medicine, Alfred Hospital and Monash University Medical School, Melbourne 3181, Australia 2 Department of Epidemiology and Preventive Medicine, Alfred Hospital and Monash ...
thorax.bmj

Clinical, radiological and pathological features of ABCA3 mutations in children

Pediatric Pulmonary Section, Department of Pediatrics, Baylor College of Medicine, Texas Children’s Hospital, Houston, Texas, USA Background: Mutations in the ABCA3 gene can result in fatal surfactant ...
thorax.bmj

Oscillatory positive expiratory pressure therapy in COPD (O-COPD): a randomised controlled trial

Background Oscillatory positive expiratory pressure (OPEP) devices are intended to facilitate sputum clearance and reduce cough, but there is limited evidence for their effectiveness in COPD, or to ...